The Medicines and Healthcare products Regulatory Agency in the UK has granted marketing authorization for KalVista Pharmaceuticals’ EKTERLY, an oral on-demand treatment for hereditary angioedema attacks in adults and adolescents. EKTERLY is the first of its kind to be approved in the UK and was previously approved by the FDA in the US on July 3, 2025. KalVista has also submitted applications for approval in the EU, Japan, and other global markets. For more health news, visit rttnews.com.

Read more at Nasdaq.: KalVista Secures UK Approval For EKTERLY, First Oral On-Demand Treatment For Hereditary Angioedema